Ra Pharmaceuticals Inc (NASDAQ:RARX) has been given an average rating of “Hold” by the six research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $19.00.
Several equities research analysts recently weighed in on the company. Credit Suisse Group decreased their price objective on Ra Pharmaceuticals from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, February 13th. ValuEngine lowered Ra Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Zacks Investment Research lowered Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. Royal Bank of Canada reissued a “buy” rating and issued a $18.00 price objective on shares of Ra Pharmaceuticals in a report on Tuesday, December 5th. Finally, BMO Capital Markets lifted their price objective on Ra Pharmaceuticals in a report on Tuesday, December 5th.
In related news, major shareholder Enterprise Associates 13 L. New bought 2,000,000 shares of the business’s stock in a transaction on Friday, February 16th. The stock was acquired at an average price of $6.00 per share, for a total transaction of $12,000,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Ra Capital Healthcare Fund Lp bought 2,500,000 shares of the business’s stock in a transaction on Wednesday, February 14th. The stock was bought at an average price of $6.00 per share, with a total value of $15,000,000.00. The disclosure for this purchase can be found here. Company insiders own 14.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of RARX. Schwab Charles Investment Management Inc. boosted its stake in Ra Pharmaceuticals by 70.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock worth $409,000 after purchasing an additional 9,000 shares during the period. Swiss National Bank bought a new position in Ra Pharmaceuticals in the 2nd quarter worth about $247,000. Alliancebernstein L.P. bought a new position in Ra Pharmaceuticals in the 2nd quarter worth about $195,000. Teachers Advisors LLC boosted its stake in Ra Pharmaceuticals by 132.8% in the 2nd quarter. Teachers Advisors LLC now owns 20,744 shares of the company’s stock worth $389,000 after purchasing an additional 11,834 shares during the period. Finally, TIAA CREF Investment Management LLC boosted its stake in Ra Pharmaceuticals by 299.0% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 31,271 shares of the company’s stock worth $586,000 after purchasing an additional 23,434 shares during the period. Institutional investors and hedge funds own 70.27% of the company’s stock.
Shares of Ra Pharmaceuticals (NASDAQ RARX) remained flat at $$6.55 on Tuesday. The stock had a trading volume of 637,462 shares, compared to its average volume of 353,413. Ra Pharmaceuticals has a 12-month low of $5.80 and a 12-month high of $27.84. The company has a market cap of $203.22, a PE ratio of -2.65 and a beta of 2.05.
WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/03/19/ra-pharmaceuticals-inc-rarx-receives-consensus-rating-of-buy-from-brokerages.html.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.